CANCER DRUGS AND 99mTc-GLUTATHIONE RADIOPHARMACEUTICAL INTERACTION TO ACHIEVE OPTIMAL RESULT OF CANCER DIAGNOSTICS IN NUCLEAR MEDICINE Teguh Hafiz A Wibawa, Ahmad Kurniawan, Isti Daruwati, Iswahyudi
Badan Riset dan Inovasi Nasional (BRIN)
Abstract
Cancer is one of the leading causes of death in the world, including Indonesia. The application of nuclear techniques in nuclear medicine plays an important role in diagnosing cancer and identify an optimal therapy. BRIN has contributed to the development of diagnostic kits, one of which is 99mTc-Glutathione. Utilizing these diagnostic kits, there is a tendency to increase the risk of drug interactions consumed by cancer patients with diagnostic kits that can lead to misinterpretation of data. This study aims to investigate the possible alteration in the pharmacokinetics profiles and biodistribution of 99mTc-Glutathione when given in combination with cancer drugs in Balb/C strain mice (Mus musculus). The study was divided into four groups of normal and model animals test. Each group is differentiated by treatment, i.e. control (I), animals test with doxorubicin treatment (II), 5-fluorouracil (III), and methotrexate (IV). Each drug is intravenously, after 5 minutes it is injected with 99mTc-Glutathione intravenously. Furthermore, the pharmacokinetics and biodistribution studies were carried out. Study of pharmacokinetics and biodistribution interaction showed that the administration of cancer drugs before administration of 99mTc-Glutathione reduces the elimination half-life and target / non-target organ ratio significantly. The target / non-target ratio of 99mTc-Glutathione (control) and 99mTc-Glutathione that combined with cancer drugs doxorubicin, 5-fluorouracil, and methotrexate in normal mices are:7.01, 1.47, 1.43, and 5.61 respectively. Whereas, the target/non-target ratio of 99mTc-Glutathione (control) and 99mTc-Glutathione that combined with cancer drugs doxorubicin, 5-fluorouracil, and methotrexate in cancer model mices are: 2.94, 1.33, 0.42, and 2.11 respectively. The results can certainly cause misinterpretation of diagnosis data. Therefore, the phenomenon of drugs and radiopharmaceutical interactions must be considered by clinicians in nuclear medicine.
